|
|||||
|
|
Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis |
|
| Authors: | Masaki Akimoto Shingo Yunoue Hideo Otsubo Tamami Yoshitama Kunihiro Kodama Kakushi Matsushita Yukio Suruga Tomohiro Kozako Shingo Toji Sachi Hashimoto Kimiharu Uozumi Takemasa Matsuda Naomichi Arima |
| Affiliation: | 1. Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan 2. Division of Hematology and Immunology, Center for Chronic Viral Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan 3. Rheumatic Disease Unit, Japanese Red Cross Kagoshima Hospital, Kagoshima, Japan 4. Medical and Biological Laboratories, Nagoya, Japan |
| Abstract: | ObjectiveThe ability of the ImmuKnow (Cylex) assay to predict the risk of infection in rheumatoid arthritis (RA) patients receiving synthetic or biological disease-modifying antirheumatic drugs (DMARDs) was examined.MethodsThe amount of adenosine triphosphate (ATP) produced by CD4+ cells in response to phytohemagglutinin was measured in whole blood from 117 RA patients without infection versus 17 RA patients with infection, and compared with results in 75 healthy controls.ResultsThe mean ATP level was significantly lower in patients with infection compared to both healthy controls (P < 0.0005) and patients without infection (P = 0.040). Also, the mean ATP level in patients without infection was significantly lower than that in healthy controls (P = 0.012). There was no correlation between the ATP level and the Disease Activity Score in 28 joints.ConclusionImmuKnow assay results may be effective in identifying RA patients at increased risk of infection, but the results showed no correlation with RA activity. Larger studies are required to establish the clinical advantages of this assay in RA treatment. |
| Keywords: | Adenovirus Osteoclast Rheumatoid arthritis (RA) Synovial fibroblast cells (SFCs) |
| 本文献已被 SpringerLink 等数据库收录！ | |